Summary

Patients with mild Alzheimer’s disease enrolled in EXPEDITION EXT had already received 80 weeks of treatment with either solanezumab or placebo. Utilizing a unique approach to the delayed-start model, researchers report that cognitive and instrumental function outcomes in delayed-start patients did not catch up to those in early-start patients, supporting the benefit of initiating treatment as early as possible.